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 To the Editor 
Causes of hospital admission have been studied in sickle cell disease 
1,2
. However, only two 
reports (one from Iran and the other from Sardinia), limited to patients with TM, have previously 
described the causes of hospital admission in thalassemia patients 
3,4
. We aimed at investigating 
the prevalence of causes of hospital admission in both TM and TI patients during the period from 
1995 to 2015 in a tertiary care center in Beirut, Lebanon. 
The study was approved by the Institutional Review Board of the American University of Beirut. 
The patients’ electronic medical records were queried using the keyword “thalassemia”. Data 
was evaluated and analyzed using STATA Data Analysis and Statistical Software 13. p-values 
less than 0.05 were considered significant. The Chi-Square test, the Student’s t-test, and linear 
regression analysis were used to analyze patient characteristics, compare lengths of stay, and 
explore associations between different variables and length of stay. 
Our cross-sectional study recruited 33 adult TM and TI patients admitted for a duration that 
exceeded 24 hours to the American University of Beirut Medical Center in Beirut, Lebanon 
during a 20-year period extending from January 1, 1995 to February 10, 2015. 205 admissions 
were analyzed. 15 patients (45.5%) had TM and 18 (54.5%) had TI. 125 admissions (61.0%) 
were in TM patients, while 80 (39.0%) were in patients who had TI. 15 patients (45.5%) were 
female and 18 (54.5%) were male. 119 admissions (58.0%) were in males (83.2% in TM and 
16.8% in TI, p < 0.001) and 86 (42.0%) were in females (30.2% in TM and 69.8% in TI, p < 
0.001). Males and females had a comparable mean length of hospital stay of around 5 days. The 
mean age of patients was 32.6 +/- 15.6 years (25.6 years in TM and 41.0 years in TI, p = 0.003).   
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 Patients with TM were more likely to have a longer hospital stay per admission when compared 
to patients with TI (6.3 days versus 3.6 days, respectively; p = 0.034). Overall, the three most 
common causes of hospitalization were transfusion therapy (54.6%), infection (12.2%), and 
chemotherapy (7.3%). In TM, the most common causes of hospital admission were transfusion 
therapy (66.4%), infection (9.6%), and bone marrow transplantation (7.2%); whereas in TI, these 
were transfusion therapy (36.3%), chemotherapy (18.8%), and infection (16.3%). Table 1 
compares the characteristics of the TM and TI patients admitted to the hospital and summarizes 
the most common causes of hospital admission in both TM and TI cohorts.  
In a linear regression model of all the hospital admissions, including age, sex, type of 
thalassemia, splenectomy status, aspirin therapy, iron chelation therapy, serum ferritin, and 
hemoglobin, a longer hospital stay was only associated with increasing age (p = 0.001). 
Transfusion therapy was the most common cause of hospital admission in both TM and TI 
patients. Second to transfusion therapy, infections were the most common cause of hospital 
admission among TM patients.  Although splenectomy was the most common reason for hospital 
admission in the Iranian study 
3
,  it was the fourth most common cause of hospitalization in TM 
patients in our cohort.  Splenectomy was not found to be associated with a longer length of 
hospital stay in our cohort of patients. Chemotherapy was the second most common reason for 
hospitalization in TI patients. This is particularly evident in patients with TI as well reflected by 
our dataset whereby all admissions for malignancy-related chemotherapy were exclusively in TI 
patients.  
This study is the first to examine the causes of hospital admission among patients with β-
thalassemia in Lebanon. It is the first in the literature to investigate such causes in patients 
belonging to the TI subset. Infections are a major cause of hospitalization in both TM and TI. 
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 This calls for antibiotic and vaccination prophylaxis in this patient population as a preventive 
measure. This study sheds the light on the need for prospective studies studying hospital 
admissions in patients with thalassemia as this study was limited to a retrospective chart review. 
Given the disparities in healthcare among different socioeconomic, demographic, and geographic 
populations, our study is likely to have suboptimally captured all characteristics of patients with 
thalassemia admitted to different hospitals across the country. This study is an important first 
step for a more geographically comprehensive approach to study the causes for hospital 
admission in thalassemia and guide preventive strategies. It will be equally important to study 
trends in hospital admissions with the establishment of outpatient transfusion centers and 
comprehensive care centers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 of 6
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
 References 
1. Aljuburi G, Laverty AA, Green SA, et al. Trends in hospital admissions for sickle cell disease in 
England, 2001/02-2009/10. J Public Health (Oxf). 2012;34(4):570-576. 
2. Teoh Y, Greenway A, Savoia H, Monagle P, Roy J, Barnes C. Hospitalisations for sickle-cell disease 
in an Australian paediatric population. J Paediatr Child Health. 2013;49(1):68-71. 
3. Karimi M, Emadmarvasti V, Hoseini J, Shoja L. Major causes of hospital admission in Beta 
thalassemia major patients in southern iran. Iranian journal of pediatrics. 2011;21(4):509-513. 
4. Origa R, Anni F, Mereu L, et al. Causes of hospital admission in children and adults with 
transfusion-dependent thalassemia in Sardinia, 2000-2015. Ann Hematol. 2017;96(6):1041-
1042. 
 
 
 
 
 
 
 
 
 
 
 
 
Page 5 of 6
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
 Table 1. Baseline characteristics of the studied cohort, and summary of the most common causes 
of hospital admission in both TM and TI cohorts. BMT: bone marrow transplant, IV: 
intravenous. 
Baseline Charactersitics  Thalassemia major Thalassemia intermedia 
Age (years, mean +/- SD)* 25.6 ± 11.0 41.0 ± 16.5 
Sex (female, %) 44 46.7 
Average length of stay (days, mean +/- SD)* 6.3 ± 4.3 3.6 ± 2.7 
Splenectomy status (%) 83.3 60 
Aspirin therapy (%) 28.6 22.2 
Iron chelation therapy (%)* 66.7 26.7 
Serum ferritin (ng/mL, mean +/- SD) 2463 ± 1891 2212 ±1590 
Hemoglobin (g/dL, mean +/- SD)* 10.6 ± 1.9 8.7 ± 2.0 
Hospital visits (mean) 6.9 5.3 
Chronic kidney disease (%) 5.6 20 
Chronic heart failure (%) 11.1 26.7 
Thrombosis (%) 16.7 20 
 
Reason for admission Thalassemia major Thalassemia intermedia 
Transfusion 83 29 
Infection 12 13 
Chemotherapy 0 15 
BMT-related 9 0 
Other 3 9 
Osteoporosis for IV bisphosphonate 3 6 
Splenectomy 5 2 
Heart failure/angina 6 0 
Liver disease  2 2 
Bone fracture 0 2 
Kidney transplant 0 1 
Thrombosis 2 1 
Total 125 80 
*: statistically significant with a t-test p-value < 0.05 
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